Case series analyzes immune-related adverse events in cancer patients receiving immunotherapy, highlighting imaging challenges.
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet their efficacy assessments using conventional imaging remain challenging due to atypical response patterns and immune-related adverse events (irAEs). We present a case series of five patients who underwent different immunotherapies for various solid cancers and were evaluated with 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT), highlighting pseudoprogression, dissociated responses, sarcoid-like reactions, and immune-mediated pancreatitis. This series underscores the pivotal role of PET/CT in distinguishing between true progression, treatment-related inflammatory changes, and emphasizes the need for physicians to be aware of these phenomena.
No takes yet. Share an insight, caveat, or question.
Edamadaka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: